THRomboprophylaxis in Individuals Undergoing Superficial endoVEnous Treatment (THRIVE)

Launched by IMPERIAL COLLEGE LONDON · Feb 9, 2023

Keywords

ClinConnect Summary

The THRIVE trial is studying whether giving medicines to reduce blood clots can help people who are undergoing treatment for varicose veins. Varicose veins are swollen veins near the skin surface that can sometimes lead to blood clots forming in deeper veins after treatment. These clots can cause swelling and pain in the leg, and in rare cases, they can travel to the lungs, which can be very serious. The trial will help determine if using blood-thinning medications after these procedures is beneficial in preventing these clots.

To participate in this study, you need to be an adult over 18 years old and scheduled for a specific type of treatment for varicose veins called endovenous intervention, which is done under local anesthesia. This treatment can use methods like radiofrequency or laser. However, certain health conditions or recent medical issues may make you ineligible, such as having a history of blood clots or bleeding disorders. If you join the study, you will receive more information about what to expect and how the trial will be conducted, ensuring you are well-informed about your participation.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adults (\>18 years)
• • Scheduled to undergo endovenous intervention of truncal varicose veins under local anaesthesia
• • Treatment technologies including radiofrequency, laser, mechanochemical, foam sclerotherapy and cyanoacrylate glue
• Exclusion Criteria:
• • Clinical indication for therapeutic anticoagulation e.g., atrial fibrillation
• • Previous personal or first-degree relative history of VTE
• • Thrombophilia
• • Female patients of childbearing potential who have a positive pregnancy test
• • A history of allergy to heparins or direct oral anticoagulants
• • A history of heparin-induced thrombocytopenia
• • Inherited and acquired bleeding disorders
• • Evidence of active bleeding
• • Concomitant major health problems such as active cancer and chronic renal and/or liver impairment
• • Known thrombocytopenia (platelets known to be less than 50 x 109
• • /l)
• • Surgery or major trauma in the previous 90 days
• • Recent ischemic stroke in the previous 90 days
• • Inability to provide consent